Beijing Foyou Pharma CO.,LTD (SHA:601089)
China · Delayed Price · Currency is CNY 20.64
-0.23 (-1.10%)
At close: Apr 28, 2026
SHA:601089 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,425 | 3,444 | 3,433 | 3,328 | 3,237 | 2,838 |
Other Revenue | 60.41 | 60.41 | 12.36 | 11.97 | 3.15 | - |
| 3,485 | 3,504 | 3,446 | 3,340 | 3,240 | 2,838 | |
Revenue Growth (YoY) | 0.34% | 1.71% | 3.17% | 3.07% | 14.18% | 11.93% |
Cost of Revenue | 1,259 | 1,225 | 1,145 | 1,128 | 1,040 | 874.82 |
Gross Profit | 2,226 | 2,279 | 2,301 | 2,212 | 2,200 | 1,963 |
Selling, General & Admin | 1,310 | 1,350 | 1,392 | 1,353 | 1,492 | 1,403 |
Research & Development | 427.08 | 403.42 | 417.37 | 353.33 | 238.4 | 176.87 |
Other Operating Expenses | 29.06 | 29.99 | 18.47 | 26.27 | 34.56 | 30.43 |
Operating Expenses | 1,769 | 1,786 | 1,829 | 1,730 | 1,767 | 1,608 |
Operating Income | 457.19 | 492.89 | 472.39 | 481.62 | 432.97 | 354.75 |
Interest Expense | -1.06 | -1.58 | -3.5 | -5.34 | -4.76 | -6.51 |
Interest & Investment Income | 25.17 | 31.18 | 49.25 | 58.02 | 35.83 | 7.98 |
Currency Exchange Gain (Loss) | -0.1 | -0.1 | 0.37 | 0.05 | 0.39 | -0.06 |
Other Non Operating Income (Expenses) | 1.44 | -0.49 | -1.28 | -0.68 | -1.18 | -2.48 |
EBT Excluding Unusual Items | 482.65 | 521.9 | 517.23 | 533.67 | 463.25 | 353.68 |
Gain (Loss) on Sale of Assets | 0.42 | -0.01 | -1.72 | 0.23 | 0.14 | 0.01 |
Asset Writedown | -1.45 | - | - | - | - | -1.13 |
Legal Settlements | - | - | - | - | - | -0.54 |
Other Unusual Items | 1.46 | 1.46 | 24.6 | 15.26 | 22.56 | 13.67 |
Pretax Income | 483.08 | 523.34 | 540.12 | 549.15 | 485.95 | 365.69 |
Income Tax Expense | 46.42 | 52.08 | 48.04 | 56.81 | 46.33 | 49.79 |
Earnings From Continuing Operations | 436.66 | 471.26 | 492.08 | 492.34 | 439.62 | 315.91 |
Minority Interest in Earnings | -2.51 | -1.9 | -3.4 | -3.57 | -0.72 | -1.44 |
Net Income | 434.14 | 469.36 | 488.67 | 488.77 | 438.9 | 314.47 |
Net Income to Common | 434.14 | 469.36 | 488.67 | 488.77 | 438.9 | 314.47 |
Net Income Growth | -10.80% | -3.95% | -0.02% | 11.36% | 39.57% | 19.70% |
Shares Outstanding (Basic) | 468 | 469 | 470 | 479 | 422 | 361 |
Shares Outstanding (Diluted) | 468 | 469 | 470 | 479 | 422 | 361 |
Shares Change (YoY) | -1.01% | -0.11% | -1.94% | 13.55% | 16.75% | 0.44% |
EPS (Basic) | 0.93 | 1.00 | 1.04 | 1.02 | 1.04 | 0.87 |
EPS (Diluted) | 0.93 | 1.00 | 1.04 | 1.02 | 1.04 | 0.87 |
EPS Growth | -9.89% | -3.85% | 1.96% | -1.92% | 19.54% | 19.18% |
Free Cash Flow | 140.77 | -36.55 | 299.23 | 189.82 | 524.36 | 335.05 |
Free Cash Flow Per Share | 0.30 | -0.08 | 0.64 | 0.40 | 1.24 | 0.93 |
Dividend Per Share | 0.500 | 0.500 | 0.500 | 0.500 | 0.400 | 0.300 |
Dividend Growth | - | - | - | 25.00% | 33.33% | - |
Gross Margin | 63.88% | 65.04% | 66.78% | 66.22% | 67.91% | 69.17% |
Operating Margin | 13.12% | 14.06% | 13.71% | 14.42% | 13.36% | 12.50% |
Profit Margin | 12.46% | 13.39% | 14.18% | 14.64% | 13.55% | 11.08% |
Free Cash Flow Margin | 4.04% | -1.04% | 8.68% | 5.68% | 16.18% | 11.81% |
EBITDA | 576.47 | 605.02 | 556.49 | 561.39 | 499.93 | 413.17 |
EBITDA Margin | 16.54% | 17.26% | 16.15% | 16.81% | 15.43% | 14.56% |
D&A For EBITDA | 119.28 | 112.14 | 84.1 | 79.77 | 66.96 | 58.42 |
EBIT | 457.19 | 492.89 | 472.39 | 481.62 | 432.97 | 354.75 |
EBIT Margin | 13.12% | 14.06% | 13.71% | 14.42% | 13.36% | 12.50% |
Effective Tax Rate | 9.61% | 9.95% | 8.89% | 10.35% | 9.53% | 13.61% |
Revenue as Reported | 2,674 | 3,504 | 3,446 | 3,340 | 3,240 | - |
Advertising Expenses | - | 28.26 | 18.06 | 45.32 | 25.17 | 26.19 |
Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.